Comprehensive multi-omics profiling identifies novel molecular subtypes of pancreatic ductal adenocarcinoma-Reference-Cited by-同舟云学术

Comprehensive multi-omics profiling identifies novel molecular subtypes of pancreatic ductal adenocarcinoma

Published:2024-11 Issue:6 Volume:11 Page:101143
ISSN:2352-3042
Container-title:Genes & Diseases
language:en
Short-container-title:Genes & Diseases

Author:

Wang Xing^ORCID,Yang Jinshou,Ren Bo,Yang Gang,Liu Xiaohong^ORCID,Xiao Ruiling,Ren Jie,Zhou Feihan,You Lei,Zhao Yupei

Publisher

Elsevier BV

Reference136 articles.

1. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States;Rahib;Cancer Res,2014

2. State of the art and future directions of pancreatic ductal adenocarcinoma therapy;Neuzillet;Pharmacol Ther,2015

3. Unicancer GI PRODIGE 24/CCTG PA.6 trial: a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas;Conroy,2018

4. EMT and dissemination precede pancreatic tumor formation;Rhim;Cell,2012

5. Stars and stripes in pancreatic cancer: role of stellate cells and stroma in cancer progression;Wilson;Front Physiol,2014

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pancreatic cancer subtyping - the keystone of precision treatment;Frontiers in Immunology;2025-04-08

2. Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy;Cancer Letters;2025-02

3. The role of epigenetic regulation in pancreatic ductal adenocarcinoma progression and drug response: an integrative genomic and pharmacological prognostic prediction model;Frontiers in Pharmacology;2024-11-21